Alliance A092204 - Clinical Trial
Email to Participate
hope.uronis@duke.edu
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
Protocol A092204, A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2819) (Cabo-Cemiplimab (REGN2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer (NCT06900595)
Principal Investigator
Diane Reidy-Lagunes, MD
Medical Oncologist
Protocol Number
IRB:
PRO00119543
NCT:
NCT06900595
Phase
Phase II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Email hope.uronis@duke.edu